Abstract 11149: Effect of Low-density Lipoprotein Cholesterol Lowering With Alirocumab on Stroke in ODYSSEY OUTCOMES

BackgroundLowering of atherogenic lipoproteins, including LDL-C, reduces the risk of ischemic stroke. However, concerns have been raised about intense lipid-lowering and a potential increased risk of hemorrhagic stroke. The ODYSSEY OUTCOMES trial compared the PCSK9 inhibitor alirocumab (ALI) with pl...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2019-11, Vol.140 (Suppl_1 Suppl 1), p.A11149-A11149
Main Authors: Jukema, J Wouter, Szarek, Michael, Zijlstra, Laurien, Bhatt, Deepak L, Bittner, Vera A, Diaz, Rafael, Drexel, Heinz, Goodman, Shaun G, Harrington, Robert A, Kim, Yong-Un, Louie, Michael J, Pordy, Robert, Reiner, Zeljko, Roe, Matthew T, Tse, Hung-Fat, Montenegro Valdovinos, Pablo Carlos, White, Harvey D, Zeiher, Andreas M, Schwartz, Gregory G, Steg, Philippe G
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundLowering of atherogenic lipoproteins, including LDL-C, reduces the risk of ischemic stroke. However, concerns have been raised about intense lipid-lowering and a potential increased risk of hemorrhagic stroke. The ODYSSEY OUTCOMES trial compared the PCSK9 inhibitor alirocumab (ALI) with placebo in 18,924 patients (pts) with recent acute coronary syndrome (ACS) and elevated atherogenic lipoproteins, including LDL-C≥70 mg/dL, despite intensive statin therapy, targeting LDL-C levels of 25–50 mg/dL and avoiding sustained LDL-C
ISSN:0009-7322
1524-4539
DOI:10.1161/circ.140.suppl_1.11149